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Background: Landiolol effectively controls rapid heart rate in atrial ﬁbrillation or ﬂutter (AF/AFL) patients
with left ventricular (LV) dysfunction. However, predicting landiolol Responders and Non-Responders
and patients who will experience adverse effects remains a challenge. The aim of this study was to clarify
the potential applicability of landiolol for rapid AF/AFL and refractory ventricular tachyarrhythmias (VTs)
in patients with heart failure.
Methods: A total of 39 patients with AF/AFL with ventricular response Z120 bpm and 12 VTs were
retrospectively enrolled. Landiolol Responders for rapid AF/AFL were deﬁned as patients whose ven-
tricular response was suppressed to less than 110 bpm or decreased by Z20% from the initial heart rate
after administration of landiolol. Responders for VTs were deﬁned as patients with no recurrent VTs
during the 24 h after the initiation of landiolol.
Results: For AF/AFL, 29 patients (74%) were Responders. In nine patients (31%), AF was spontaneously
terminated after starting landiolol. Eight Non-Responders (80%) needed to have AF terminated by car-
dioversion. Left ventricular ejection fraction (LVEF) at baseline was signiﬁcantly associated with landiolol
efﬁcacy. For VTs, seven patients (58%) were Responders, and smaller LV diastolic and systolic diameters
were associated with landiolol efﬁcacy. Hypotension after landiolol treatment occurred in 5 of 51
patients, and lower LV systolic function was associated with the development of adverse events.
Conclusions: Landiolol is effective in patients with heart failure not only due to rapid AF/AFL but also due
to VTs. However, preserved LVEF is important for efﬁcacy and safety in landiolol treatment.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Rapid ventricular contractions caused by various tachycardias,
such as atrial ﬁbrillation (AF), atrial ﬂutter (AFL), atrial tachycardia
(AT), ventricular tachycardia, or even frequent ventricular ectopic
beats, can induce left ventricular (LV) systolic dysfunction in
clinical settings [1,2]. Tachypacing is one of the most usefulblished by Elsevier B.V. All rights
r Medicine, National Cerebral
ita, Osaka 565-8565, Japan.methods to induce LV dysfunction in an animal model of heart
failure (HF) [3] as a consequence of the extracellular (Ca2þ over-
load) and cellular modiﬁcation of various ion channels and
transporters [4,5], and beta-adrenergic receptors [3,6,7]. Beta-
blockers have both negative chronotropic action and a pleio-
tropic effect on cardioprotection, leading to the recovery of
impaired LV function in various structural and rhythm disorders,
including idiopathic cardiomyopathy [8] and ventricular tachy-
cardia [9]. The antiarrhythmic effects of β-blockers are well-
known, although their negative inotropic and even proarrhythmic
action in some cases with advanced HF [10] may be non-
negligible.reserved.
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intravenous β-adrenergic blocker that is rapidly metabolized to
inactive forms, and has relatively smaller negative inotropic effects
on the cardiac output [11]. Landiolol is more effective for con-
trolling rapid heart rate than digoxin in AF/AFL patients with LV
dysfunction [12] and is also applicable for rhythm maintenance
after catheter ablation [13]. A low-dose β1-blocker, landiolol, in
combination with milrinone, improves intracellular Ca2þ handling
in failing cardiomyocytes [14]. However, there are only a few
clinical practice reports that examine how we can predict landiolol
Responders and Non-Responders and patients who will experi-
ence adverse effects [15,16], especially in a study population
including patients with much lower LVEF (o25%). The aim of this
study was to clarify the potential applicability of landiolol for rapid
AF and refractory ventricular tachyarrhythmias (VTs) in patients
with HF.2. Methods
2.1. Patients and data collection
From May 2013 to May 2014, a total of 39 patients with rapid
AF (72711 years old, 51% male, average heart rate 152719 bpm)
and 12 patients with refractory VTs (59715 years old, 75% male,
mean cycle length of 4157105 ms) who were treated with land-
iolol at the National Cerebral and Cardiovascular Center and Shiga
University of Medical Sciences were retrospectively surveyed.
Rapid atrial tachyarrhythmia was diagnosed if a patient had AF,
AFL, or AT with ventricular response Z120 bpm. AF subtypes were
classiﬁed as paroxysmal (PAF), persistent AF (Per-AF), or long-
standing Per-AF according to the American Heart Association/
American College of Cardiology/Heart Rhythm Society (AHA/ACC/
HRS) guidelines [17].
Refractory VTs were deﬁned as repetitive VTs, including sus-
tained (Z30 s) or incessant nonsustained (o30 s) ventricular
tachycardia (ventricular rate Z100 bpm) or ventricular ﬁbrillation
(VF), if one or more class III antiarrhythmic drugs were adminis-
tered. Electrical storm was deﬁned if repetitive sustained ven-
tricular tachycardia occurred three times or more in 24 h [18,19].
In patients with implanted deﬁbrillators (implantable cardioverter
deﬁbrillators [ICDs] or cardiac resynchronization therapy with
deﬁbrillation capability [CRT-Ds]), a discharge of appropriate
shock therapy was applied for sustained VTs even if this had ter-
minated within the duration mentioned above. The incidence of
VTs was calculated for 24 h before and after administration of
landiolol with reference to preceding research using parenteral
antiarrhythmic agents for refractory VTs [20]. Concomitant drugs
other than landiolol were unrestricted. This study was approved
by the ethics committee of the National Cerebral and Cardiovas-
cular Center (M26-126).
2.2. Echocardiographic and electrophysiological indices
Echocardiography was performed to evaluate LV systolic func-
tion by calculating dimensions and left ventricular ejection frac-
tion (LVEF). In patients with rapid AF, LVEF was evaluated during
both an acute episode with a rapid heart rate and during stable
status after the heart rate was controlled, because LVEF may
decrease when rapid AF persists. In patients with VTs, LVEF was
measured after they were stabilized. Serum B-type natriuretic
peptide (BNP) level was measured before and after administration
of landiolol. QT (QTc) interval at baseline was measured and cal-
culated by Bazett’s formula if an electrocardiogram (ECG) could be
obtained before tachyarrhythmias.2.3. Landiolol initiation and titration
For patients with rapid AF/AFL, landiolol was administered
intravenously at the lowest recommended dosage of 1 μg/min/kg,
which is speciﬁed as the minimal dosage for patients with LV
dysfunction [12].
For patients with VTs, oral or intravenous class III antiar-
rhythmic drugs were administered ﬁrst. However, if these had no
or incomplete effect, the addition of landiolol was initiated using
the same titration method as that for rapid AF. If landiolol was
tolerated, the dosage could be titrated upward stepwise with
careful monitoring by 1 μg/min/kg up to 10 μg/min/kg, until a
positive or adverse effect appeared.
2.4. Efﬁcacy and safety of landiolol
Landiolol Responders for rapid AF were deﬁned as patients in
whom the ventricular response was suppressed to less than
110 bpm or decreased by Z20% from the initial heart rate after
administration of landiolol [12]. The time to achieve the reduction
to the target heart rate was also examined. If the target heart rate
reduction could not be achieved within 3 h after landiolol
administration, patients were classiﬁed as Non-Responders.
On the other hand, Responders for VTs were deﬁned as patients
with no recurrent VTs for 24 h after landiolol initiation as com-
monly used [20–22]. Non-Responders were deﬁned as patients in
whom more than one episode of VTs was observed during the 24 h
after landiolol initiation.
Adverse effects were deﬁned as follows: (1) blood pressure
reduction to less than 80 mmHg, (2) heart rate drop to less than
50 bpm, or (3) other hemodynamic deterioration, including
hypoxia due to congestion. When adverse events were observed,
landiolol was discontinued, even if favorable antiarrhythmic
effects were seen.
2.5. Statistics
Numerical data are reported as either mean7standard devia-
tion (SD), standard error (SE), or median and interquartile range,
as appropriate. To compare numerical data between two groups,
an unpaired t-test or Mann–Whitney U test was used. The chi-
square test was used to compare the prevalence of characteristics
between two groups. A two-tailed probability (p) value less than
0.05 was accepted as signiﬁcant. A software package (JMP 9.0; SAS
Institute Inc., Cary, NC, USA) was used for statistical analysis.3. Results
3.1. Rapid atrial arrhythmias
3.1.1. Baseline characteristics
The baseline characteristics of 39 patients with rapid AF are
shown in Table 1. In these patients, 34 had AF, one had combined
AF and AFL, and 4 had AT. The baseline heart rate was higher in
patients with AT (176729 bpm) than in patients with AF
(149716 bpm) (p¼0.006) and patients with AFL with AF
(145 bpm). Twelve patients (31%) had ischemic heart disease
(IHD). Other etiologies of HF were valvular heart disease (6
patients), hypertensive heart disease (3), constrictive pericarditis
(1), cardiac amyloidosis (1), idiopathic dilated cardiomyopathy (1),
hypertrophic cardiomyopathy (1), cardiac tamponade (1), con-
genital heart disease (1), and thyrotoxic crisis (1). The remaining
11 patients were considered to have tachycardia-induced HF
without preexisting structural heart disease. Thirty-four patients
(87%) presented with severe heart failure (New York Heart
Table 1
Baseline clinical characteristics comparing landiolol Responders (RSP) and Non-Responders (Non-RSP) with rapid AF/AFL/AT.
Total (n¼39) RSP (n¼29) Non-RSP (n¼10) p Value
Age, yr 72711 73710 69715 0.33
Male, n (%) 20 (51) 15 (52) 5 (50) 0.93
NYHA III/IV, n (%) 34 (87) 25 (86) 9 (90) 0.76
IHD, n (%) 12 (31) 10 (34) 2 (20) 0.39
PAF/Per-AF 21/18 16/13 5/5 0.78
Heart rate, bpm 152719 152719 153720 0.83
Blood pressure, mmHg 116720 117720 113723 0.60
BNP, pg/mla 421 (151–864) 387 (134–663) 820 (321–1699) 0.23
LVEF, % 34716 37716 25712 0.049
LVDD, mm 49710 49711 4776 0.57
LVDS, mm 37711 36711 3979 0.63
eGFR, ml/min/1.73 m2 45722 42723 56715 0.06
Digoxin, n (%) 13 (33) 8 (28) 5 (50) 0.20
β-Blocker, n (%) 17 (44) 14 (48) 3 (30) 0.31
Amiodarone, n (%) 3 (8) 2 (7) 1 (10) 0.76
ACEI/ARB, n (%) 11 (28) 9 (23) 2 (5) 0.50
Aldosterone
antagonists
7 (18) 5 (13) 2 (5) 0.84
Inotrope infusion, n (%) 13 (33) 8 (28) 5 (50) 0.20
Vasodilators, n (%) 14 (36) 9 (23) 5 (13) 0.28
Intubation, n (%) 12 (31) 7 (24) 5 (50) 0.14
Maximum dose, μg/kg/
min
4.873.3 4.573.0 5.574.2 0.40
After treatment
Heart rate, bpm 88729 79719 114738 0.0005
Blood pressure, mmHg 103720 104719 103724 0.90
BNP, pg/mla 292 (135–650) 291 (126–683) 394 (206–627) 0.70
LVEF, % 43716 44715 39719 0.43
LVDD, mm 4978 4978 4976 0.91
LVDS, mm 3779 36710 3979 0.58
Cardioversion, n (%) – 8 (80) NA
Adverse event, n (%) 3 (8) 2 (7) 1 (10) 0.76
Sinus rhythm, n (%) 21 (54) 16 (55) 5 (50) 0.93
β-Blocker, n (%) 29 (74) 22 (76) 7 (70) 0.72
Digoxin, n (%) 4 (10) 2 (7) 2 (20) 0.28
Infusion duration, daysa 3 (1-7) 3 (1-8) 2 (1-4) 0.08
Survival, n (%) 31 (79) 24 (83) 7 (70) 0.40
NYHA, New York Heart Association functional class; IHD, ischemic heart disease; PAF, paroxysmal atrial ﬁbrillation; per-AF, persistent atrial
ﬁbrillation; BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; LVDD, left ventricular end-diastolic dimension; LVDS, left
ventricular end-systolic diameter; eGFR, estimated glomerular ﬁltration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angio-
tensin receptor blocker.
a Variables were represented as median (interquartile range).
Fig. 1. Heart rate change with landiolol for rapid atrial arrhythmias. Each data set
represents heart rate before, during, and after treatment with landiolol. In
Responders (RSP), heart rate was signiﬁcantly reduced by 36.8% from baseline
(152719 to 96717 bpm, po0.0001) with landiolol for 2.271.8 h. In contrast, in
Non-Responders (Non-RSP), heart rate was unchanged with landiolol (153720 to
137722, p¼0.11) for 1.970.7 h.
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patients (31%) required mechanical ventilation because of severe
hypoxia due to congestive heart failure. One-third of patients had
been treated with inotrope infusion (dopamine alone in 2, dobu-
tamine alone in 1, noradrenaline alone in 1, a combination of
dopamine plus dobutamine in 6, dopamine plus noradrenaline in
1, and dobutamine plus noradrenaline in 2. The use of these ino-
trope infusions was not statistically different between the land-
iolol Responders and Non-Responders (Table 1). Vasodilators were
used in combination with landiolol in 14 patients (carperitide in 8,
nitrate in 4, nicorandil in 1, and nicardipine in 1). Before landiolol
treatment, intravenous digoxin was attempted in 13 patients (33%)
at a uniform dosage of 0.25 mg; however, the heart rate was only
reduced from 158718 to 148721 bpm (p¼0.20). Oral β-blockers
were prescribed in 17 patients (44%) at baseline (bisoprolol in 11
[2.78 mg per day on average] and carvedilol in 6 [6.04 mg per day
on average]). Previous oral β-blocker usage was independent of
the effect of landiolol.
3.1.2. Responders vs. Non-Responders
Of 39 patients with rapid AF/AFL/AT, 29 (74%) were Responders
and 10 (26%) were Non-Responders. In Responders, the heart rate
was reduced by 36.8% from baseline (152719 to 96717 bpm,
po0.0001) for 2.271.8 h (Fig. 1, middle). In contrast, in Non-Responders, the heart rate was unchanged during landiolol
administration (153720 to 137722, p¼0.11) for 1.970.7 h
(Fig. 1, right). Furthermore, in 9 (31%) of the 29 Responders, AF was
Fig. 2. Change in LVEF with landiolol in Responders vs. Non-Responders (A), and in
LVEF o25% vs. Z25% (B). (A) In Responders, average LVEF was not changed after
landiolol therapy (left panel), whereas in Non-Responders, LVEF after treatment
tended to be increased (right panel). (B) LVEF was signiﬁcantly increased in patients
with much lower LVEF (o25%) at baseline (left panel), whereas there was no
change in those with relatively higher LVEF (Z25%) (right panel).
Table 2
Clinical characteristics comparing patients with rapid AF and LVEF Z25% and
o25%.
LVEFZ25% LVEFo25% p Value
N¼28 N¼9
Age, yr 71710 73717 0.67
Male, n (%) 416 (57) 4 (44) 0.51
NYHA III/IV, n (%) 23 (82) 9 (100) 0.17
IHD, n (%) 10 (36) 2 (22) 0.45
PAF/Per-AF 16/12 4/5 0.51
Heart rate, bpm 152720 156713 0.63
Blood pressure, mmHg 117722 116718 0.85
BNP, pg/mla 359 (266-747) 558 (496-996) 0.14
LVEF, % 40713 1474 o .0001
LVDD, mm 48711 5077 0.60
LVDS, mm 34711 4476 0.04
eGFR, ml/min/1.73 m2 47.7721.8 42.2721.4 0.52
Digoxin, n (%) 8 (29) 4 (44) 0.38
β-Blocker, n (%) 13 (46) 4 (44) 0.92
Amiodarone, n (%) 3 (11) 0
Inotrope infusion, n (%) 8 (29) 3 (33) 0.79
Intubation, n (%) 7 (25) 3 (33) 0.62
Maximum dose, μg/kg/min 4.472.8 6.374.6 0.14
Responder, n (%) 22 (79) 5 (56) 0.07
After treatment
Adverse effect, n (%) 1 (4) 2 (22) 0.10
LVEF, % 45716 32715 0.049
Sinus rhythm, n (%) 16 (57) 4 (44) 0.64
BNP, pg/mla 264 (121–634) 463 (178–1138) 0.70
β-Blocker, n (%) 22 (79) 5 (56) 0.18
Survival, n (%) 24 (86) 5 (56) 0.06
Abbreviations as in Table 1.
a Variables were represented as median (interquartile range).
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additional antiarrhythmic drug after landiolol administration. In
contrast, 8 of the 10 Non-Responders underwent cardioversion
using an external deﬁbrillator. In 6 of these patients, AF was suc-
cessfully terminated as sinus rhythm, and 5 maintained sinus
rhythm. Landiolol was continued for a median of 3 and 2 days in
Responders and Non-Responders, respectively. On ﬁnal observa-
tion, sinus rhythm was maintained in 21 patients (16 Responders,
5 Non-Responders), independent of the effect of landiolol.
Table 1 compares clinical characteristics between Responders
(n¼29: 25 AF, 1 AFþAFL, and 3 AT) and Non-Responders (n¼10: 9 AF
and 1 AT). Of several hemodynamic indices, only LVEF at baseline was
signiﬁcantly lower in Non-Responders compared with Responders. The
initial heart rate, NYHA functional class, and LV dimensions were
similar between both groups. BNP value before treatment was also not
signiﬁcantly different between Responders and Non-Responders. Fur-
thermore, a change in BNP level was not associated with the effect of
landiolol (BNP decreased by 1197117 [SE] pg/ml in Responders, and
3457220 [SE] pg/ml in Non-Responders, p¼0.39), suggesting that
landiolol did not worsen HF. In terms of hemodynamic changes, both
LVEF and BNP level after treatment were comparable between
Responders and Non-Responders (LVEF: 44715% vs. 39719%,
p¼0.43; BNP: 292 [IQR: 126–683] vs. 394 [IQR: 206–627], p¼0.70)
(Table 1; after treatment). To exclude the beneﬁcial effect of AF termi-
nation, we separately analyzed the change of LVEF in patients with or
without AF termination during treatment. There was no signiﬁcant
improvement in LVEF in Responders and Non-Responders (Fig. 2A),
independent of rhythm status after treatment. Among Non-Responders,
there was a tendency toward a small but insufﬁcient increase in LVEF in
patients with sinus rhythm after treatment (Supplemental ﬁgure, right).3.1.3. Landiolol for patients with LVEFo25%
Lower LVEF was the only predictor of Non-Responders to
landiolol therapy. Thus far, we have compared the effects of
landiolol between patients with LVEFZ25% (n¼28) and o25%
(n¼9) at baseline (Table 2), except for 2 patients lacking LVEF data
during an acute episode. No statistical signiﬁcance was found
between the two groups for underlying etiology, initial heart rate,
premedication, maximum dose, and efﬁcacy of landiolol. Patients
with LVEF 425% usually maintained sinus rhythm until the end of
landiolol therapy, whereas average LVEF did not change (from
40713% to 45716%, p¼0.24) (Fig. 2B, left). In contrast, LVEF was
signiﬁcantly improved in patients with LVEF o25% (from 1474%
to 32715%, p¼0.004) since most underwent cardioversion that
terminated AF as sinus rhythm (Fig. 2B, right).
3.1.4. Rate control therapy after landiolol
Oral β-blockers were prescribed at discharge in 29 patients
(74%) (bisoprolol in 24 [3.37 mg per day on average], metoprolol in
1 [20 mg per day], and carvedilol in 4 [5.42 mg per day on aver-
age]). Of 29 Responders, 7 did not receive oral β-blocker therapy at
ﬁnal observation because of in-hospital death in 2, severe chronic
obstructive pulmonary disease in 1, symptomatic bradycardia in 2,
hospital transfer with parenteral treatment in 1, and low cardiac
output due to mitral regurgitation while awaiting cardiac surgery
in 1. Although landiolol was ineffective, oral β-blockers could be
used in all the Non-Responders who were discharged alive (biso-
prolol in 6 [2.40 mg per day on average], carvedilol in 1 [5 mg per
day]); the remaining 3 patients died in-hospital.
3.2. Ventricular tachyarrhythmias
3.2.1. Baseline characteristics
The baseline characteristics of 12 patients with landiolol treat-
ment for VTs (6 with electrical storm, 4 with sustained VT, and 2 with
Table 3
Baseline clinical characteristics comparing landiolol Responders (RSP) and Non-Responders (Non-RSP) with lethal VTs.
Total (n¼12) RSP (n¼7) Non-RSP (n¼5) p Value
Age, yr 59715 59718 60712 0.86
Male, n (%) 9 (75) 5 (71) 4 (80) 0.74
LVEF, % 26717 32719 18710 0.17
LVDD, mm 62713 5579 71713 0.02
LVDS, mm 52715 44711 64713 0.02
eGFR, ml/min/1.73 m2 48721 45721 53724 0.53
β-Blocker, n (%) 10 (83) 6 (86) 4 (80) 0.79
Amiodaronea, n (%) 10 (83) 7 (100) 3 (60) 0.07
Inotrope infusion, n (%) 1 (8) 1 (14) 0 (0) 0.38
VT subclass, n
Electrical storm 6 4 2
Sustained VT 4 2 2 NA
Incessant NSVT 2 1 1
VT CL, ms 4157105 382773 4607134 0.22
VT QRS, ms 186740 170736 213735 0.09
VT morphology, n
LBBB 1 0 1
RBBB 10 7 3 NA
Unclassiﬁed 1 0 1
VT QRS axis: inferior/superior 6/6 3/4 3/2 0.56
Blood pressure before treatment, mmHg 92716 95715 86718 0.40
Initial QTc, ms 504792 5187112 484759 0.56
ICD/CRT-D, n (%) 10 (83) 5 (71) 5 (100) 0.19
Landiolol max dose, μg/kg/min 4.271.6 (SE) 5.272.6 (SE) 2.771.78 (SE) 0.47
BNP before treatment, pg/mlb 612 (116–971) 624 (335–1273) 462 (73–845) 0.35
BNP after treatment, pg/ml 166 (137–540) 251 (72–511) 166 (162–1327) 0.36
Adverse event, n (%) 2 (17) 1 (14) 1 (20) 0.79
NSVT, non-sustained ventricular tachycardia; CL, cycle length; LBBB, left bundle branch block; RBBB, right bundle branch block; CRT-D,
cardiac resynchronization therapy with deﬁbrillation capability; ICD, implantable cardioverter deﬁbrillator; SE, standard error, other
abbreviations as in Tables 1 and 2.
a Oral and/or parenteral prescription.
b Variables were represented as median (interquartile range).
Table 4
Characteristics of patients with adverse effects (AE).
#1 #2 #3 #4 #5
Adverse effect Hypotension
Arrhythmia VTs PAF Chronic AF VTs Chronic AF
Age, yr 66 92 80 74 70
Sex F F M M M
LVEF before treat-
ment, %
– 10 15 – 32
LVEF before treat-
ment, %
15 10 25 20 35
RSP/Non-RSP Non-RSP Non-RSP RSP RSP RSP
Initial heart rate, bpm 110 170 147 200 140
Underlying heart
disease
Sarcoidosis TIC CP NICM VHD
RSP, Responder; TIC, tachycardia-induced cardiomyopathy; CP, constrictive peri-
carditis; NICM, non-ischemic cardiomyopathy; VHD, valvular heart disease, other
abbreviations as in Tables 1–3.
Table 5
Comparison between patients with and without adverse effects (AE).
AE (þ) AE () p Value
N¼5 N¼46
VTs/AF, n 2/3 10/36 0.36
Age, yr 76710 68713 0.18
Blood pressurea, mmHg 102710 112723 0.38
LVEFb, % 1878 33717 0.06
LVDDb, mm 64712 51712 0.03
LVDSb, mm 55712 40714 0.046
BNP, pg/mlc 1568 (294–2482) 455 (268–794) 0.15
β-Blocker, n (%) 1 (20) 26 (57) 0.12
Amiodarone, n (%) 2 (40) 11 (24) 0.43
Inotrope infusion, n (%) 2 (40) 12 (26) 0.51
Landiolol max dose, μg/kg/min 3.671.8 4.774.1 0.56
Abbreviations as in Tables 1–4.
a Variables during acute situation.
b Variables during stable state.
c Variables represented as median (interquartile range).
Fig. 3. Maximum dose and efﬁcacy of landiolol for rapid atrial arrhythmias.
Number of patients administered the maximum dose of landiolol who achieved the
endpoint; based on both heart rate o110 bpm or Z20% decrease in the heart rate
from baseline within 3 h after initiation.
Y. Wada et al. / Journal of Arrhythmia 32 (2016) 82–8886incessant nonsustained VT) are shown in Table 3. All patients had
nonischemic etiologies. Ten of 12 patients received ICDs (6 CRT-D,
4 ICD) and 2 wore external LV assist devices before the events.
Hemodynamic collapse during VTs occurred in two patients and one
required a temporary cardiopulmonary assist device. Oral β-blockers
were prescribed in 10 patients. Oral class III antiarrhythmic agents
were prescribed in 9 patients (amiodarone in 4, sotalol in 2, amio-
darone combined with sotalol in 3). Parenteral class III antiar-
rhythmic agents were administered before landiolol in 7. Five
patients were not administered parenteral class III antiarrhythmics
because all had received one or two oral maintenance class III anti-
arrhythmics and 4 presented with a prolonged QTc duration.
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Of 12 patients with refractory VTs, 7 had no recurrent VTs during
continuous landiolol infusion. A comparison between Responders and
Non-Responders for VTs is shown in Table 3. Both LV end-diastolic
(LVDD) and end-systolic dimension (LVDS) were signiﬁcantly larger in
the Non-Responder group compared with the Responder group. BNP
level was markedly high in both groups before landiolol infusion. LVEF
was comparable, while LV dimension was signiﬁcantly enlarged in
Non-Responders. Antiarrhythmic pretreatment, especially amiodarone
(oral or parenteral), was prone to this response.
Electrophysiological study and catheter ablation were performed
in 4 patients (2 Responders and 2 Non-Responders). Non-reentrant
VTs corresponding to clinical VTs were induced in 2 of 2 Responders,
whereas reentrant VTs were provoked in 2 of 2 Non-Responders.
Catheter ablation eliminated clinical VTs in 3 of these 4 patients.
3.3. Adverse effects of landiolol (AF and VTs)
Adverse effects, all involving hypotension, were observed in
5 patients as detailed in Table 4 (10% of all patients: 3 in the AF
group, 2 in the VT group, 3 in Responders). However, landiolol was
discontinued in all ﬁve patients immediately after adverse effects
developed.
We also compared patients with (AE [þ]) or without adverse
effects (AE []). Table 5 shows that the incidence of adverse
effects was associated with impaired LV function, rather than with
the dose of landiolol.4. Discussion
A reduction in rapid ventricular response is one of the most
effective therapeutic strategies in patients with tachycardia-
related HF. This retrospective multicenter survey revealed that
landiolol, an ultra-short-acting β1-selective blocker, was effective
in more than half of patients with HF not only in association with
rapid AF/AFL, but also refractory VTs, which had already been
treated with other antiarrhythmic agents, mainly amiodarone.
Much lower LVEF and larger LV diastolic or systolic diameters were
possible predictors for the efﬁcacy and safety of landiolol
treatment.
4.1. Practical use of landiolol for rapid AF
In acute decompensated HF, the rapid ventricular response is
both the cause and consequence of hemodynamic deterioration
[23]. Of several negative chronotropic agents, only digoxin and β-
blockers are theoretically of practical use in HF patients with
reduced LVEF [24]. Recently, the J-Land study [12] demonstrated
that landiolol was more effective for controlling the rapid heart
rate than digoxin in AF/AFL patients with LV dysfunction. In
comparison with the J-Land study, landiolol in this clinical survey
was used in patients with more unfavorable situations, such as a
higher ventricular rate in atrial arrhythmias, a higher prevalence of
mechanical ventilation, more severe renal dysfunction, and a
higher prescribed dose of oral β-blockers at baseline. Despite these
unfavorable clinical situations, landiolol could reduce the heart
rate within 2.271.8 h after starting an infusion in Responders.
Furthermore, the maximum dose of landiolol varied from 1 to
10 mg/kg/min and was independent of the efﬁcacy (Fig. 3); this is
consistent with the previous study [12]. With regard to speciﬁc
dosage and efﬁcacy among the10 Non-Responders in the AF/AFL/
AT study, 1 required immediate cardioversion because of
decreasing blood pressure at 3 μg/kg/min, and 4 continued on
landiolol up to 9 μg/kg/min. Among the remaining 5, mandatory
cardioversion was performed in 3; 2 of these were performed after190 and 195 min at 3.2 μg/kg/min and 2 μg/kg/min, respectively,
and were considered Non-Responders; 1 underwent attempted
cardioversion after 20 h of landiolol at 2 μg/kg/min. We do not
completely exclude the possibility of “potential responders”, but
none of the Non-Responders received cardioversion before ade-
quate titration of landiolol. Furthermore, in the J-Land study,
landiolol dosage and efﬁcacy were not directly correlated. These
ﬁndings suggest that the 10 patients were actually Non-
Responders. Thus, in clinical practice, landiolol has higher
potency for reducing rapid heart rate in patients with much more
severe LV dysfunction; however, prediction of the efﬁcacy or
adverse effects remains unresolved.
4.2. Responders vs. Non-Responders to landiolol for rapid AF
In this study, most of the baseline clinical parameters between
Responders and Non-Responders were similar. However, of several
hemodynamic indices, only LVEF might be associated with the
response to landiolol. On the basis of the force-frequency rela-
tionship, rapid ventricular response can facilitate cardiotonic
action in both a single cardiomyocyte and in the non-failing heart;
however, tachypacing promotes an opposite action, thus decreas-
ing the hemodynamic state in the failing heart [23]. It is difﬁcult to
estimate the force-frequency relationship in individuals with HF,
and even more challenging to determine the optimal heart rate for
the patients. This study suggested that landiolol may not be
appropriate for HF patients with extremely low LVEF. However,
landiolol is an ultra-short-acting β1-selective blocker, and can be
stopped and quickly washed-out if it is ineffective or induces AE.
In the J-Land study [12], landiolol was shown to rapidly reduce
the heart rate compared with digoxin. There were no signiﬁcant
differences between the two groups in terms of the change in
clinical parameters at ﬁnal observation. Furthermore, the rapid
decrease in the heart rate was not associated with symptomatic
relief in those patients. In this study, heart rate reduction was
more immediate in Responders compared with Non-Responders;
however, there was no signiﬁcant difference in the hemodynamic
parameters, including systolic blood pressure, LVEF, BNP level, and
LV dimensions after treatment. Thus, as shown in Table 1, landiolol
treatment does not always affect the prognosis of patients.
4.3. Practical use of landiolol for lethal VTs
A previous study suggested that the efﬁcacy of landiolol for
electrical storm due to the acute coronary syndrome depends on
the patient’s general condition, such as a lower Acute Physiology
and Chronic Health (APACHE) II score [25]. On the other hand,
patients in this study had nonischemic cardiomyopathy, no
apparent progressive organ failure, and were under treatment
with strong antiarrhythmic therapy including prior device
implantation. A class III antiarrhythmic agent, amiodarone, sup-
presses reentrant VTs by multiple mechanisms, but mainly by
prolongation of ventricular refractory periods. In this study,
amiodarone was administrated in all landiolol Responders, and
60% (3 of 5) of the Non-Responders (p¼0.07). Landiolol, a selective
β1-adrenergic receptor inhibitor, may suppress VTs due to trig-
gered activities rather than reentrant mechanisms. Thus, landiolol
can be useful for some patients with recurrent unstable VT or VF
storm, even after class III antiarrhythmics have been administered.
To assess efﬁcacy, we used 24-hour observation for controlling
VTs in accordance with previous studies [20–22,25]. The
mechanisms of sustained VT and electrical storm, incessant NSVT,
and VF are sometimes different, but the available prior research
strongly indicated that 24 h without VT/VF events should be
enough to evaluate at least the short-term efﬁcacy of treatment for
lethal ventricular arrhythmias.
Y. Wada et al. / Journal of Arrhythmia 32 (2016) 82–88884.4. Study limitations
There are some important limitations. First, this study was
retrospective and nonrandomized, and employed a small sample
size at two cardiovascular hospitals. In addition, the follow-up
period was short. Further study is required to investigate the
efﬁcacy and safety of landiolol in the long term. Second, we per-
formed this study to evaluate the efﬁcacy and safety of landiolol in
patients with atrial or ventricular tachyarrhythmias. As such, we
did not compare landiolol with digoxin or a control (only con-
ventional therapy).5. Conclusion
Landiolol is a new therapeutic option for (1) rapid AF in
patients with decompensated HF and reduced LVEF, and has
minimal adverse effects; and (2) refractory VTs in patients with
nonischemic cardiomyopathy who have been receiving class III
antiarrhythmic pretreatment. Further clinical evidence is needed
to clarify the efﬁcacy of landiolol in combination with other anti-
arrhythmic or heart rate control drugs.Funding
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